Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
APLS Stock Chart & Stats
$17.57
-$1.37(-3.96%)
At close: 4:00 PM EST
$17.57
-$1.37(-3.96%)
Day’s Range― - ―
52-Week Range$16.10 - $30.48
Previous CloseN/A
Volume215.04K
Average Volume (3M)2.14M
Market Cap
$2.25B
Enterprise Value$2.22B
Total Cash (Recent Filing)$467.76M
Total Debt (Recent Filing)$486.31M
Price to Earnings (P/E)141.4
Beta1.01
Next Earnings
Apr 30, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding127,829,910
10 Day Avg. Volume2,482,358
30 Day Avg. Volume2,136,612
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)8.55
Price to Sales (P/S)3.15
P/FCF Ratio70.33
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue2.21
Enterprise Value/Gross Profit2.46
Enterprise Value/Ebitda31.73
Forecast
1Y Price Target
$31.27Price Target Upside77.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$866.05M
Bulls Say, Bears Say
Bulls Say
Commercial Expansion In Rare Kidney DiseaseEmpaveli's broad label that includes pediatric and post-transplant patients, combined with strong payer coverage and an active patient identification program, should drive steady sales expansion in rare kidney indications.
Market LeadershipSyfovre's status as the only approved therapy targeting the C3 pathway for geographic atrophy with a dominant market share and demonstrated durable lesion-growth reduction supports continued adoption and significant revenue potential.
Product Delivery And Diagnostic ToolsIntroduction of a prefilled syringe together with AI-enabled OCT imaging and emerging long-term outcome data could simplify clinic workflows, encourage earlier treatment starts, and materially boost Syfovre uptake.
Bears Say
Patient Access And Assistance VolatilityDisruption or reclosure of patient-support funding and lack of copay assistance can constrain Syfovre uptake and shift patients toward lower-cost alternatives, reducing treatment continuity.
Revenue And Margin PressureElevated gross-to-net discounts alongside higher selling and administrative costs could compress reported revenue and widen net losses, limiting near-term financial improvement.
Safety RiskPotential recurrence of vasculitis safety events represents a material risk that could diminish physician confidence and slow Syfovre adoption if incidence increases.
Apellis Pharmaceuticals News
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $16.10 and its highest was $30.48 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Apellis Pharmaceuticals Inc’s market cap is $2.25B.
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Apr 30, 2026 which is in 35 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Feb 24, 2026. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.374 by -$0.096.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -0.35.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 127,829,910 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.374. Following the earnings report the stock price went down -1.513%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in APLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apellis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.27 (77.97% Upside)
$31.27 (77.97% Upside)
Blogger Sentiment
Neutral
APLS Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 129.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.21%
12-Months-Change
Fundamentals
Return on Equity
8.20%
Trailing 12-Months
Asset Growth
21.49%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
APLS Company Deck
APLS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple commercial and scientific positives: robust EMPAVELI early launch metrics (>5% market penetration, 267 start forms), SYFOVRE injection growth (~17% YoY) and strong 5‑year clinical data, a progressing pipeline with upcoming readouts and regulatory milestones, and a solid cash position ($466M). Offsetting these strengths are near-term revenue headwinds from elevated free goods and high gross-to-net adjustments (mid‑to‑high‑20% range), seasonal and quarter-to-quarter variability for launches in ultra-rare populations, modestly higher 2026 operating expenses to fund pivotal trials, and a $94M convertible debt maturing in 2026. Overall, the highlights around commercial traction, data readouts, pipeline advancement and financial flexibility outweigh the challenges, though execution risks and revenue timing uncertainty remain.View all APLS earnings summariesAPLS Stock 12 Month Forecast
Average Price Target
$31.27
▲(77.97% Upside)
Technical Analysis
Zai Lab
―
Crinetics Pharmaceuticals
―
―
Mirum Pharmaceuticals
―
MoonLake Immunotherapeutics
―
Ownership Overview
3.99% Insiders
17.52% Mutual Funds
42.22% Other Institutional Investors
14.96% Public Companies and Individual Investors